Handelsbanken Fonder AB Sells 8,200 Shares of Dynavax Technologies Corporation $DVAX

Handelsbanken Fonder AB decreased its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 16.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 41,500 shares of the biopharmaceutical company’s stock after selling 8,200 shares during the period. Handelsbanken Fonder AB’s holdings in Dynavax Technologies were worth $412,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its stake in Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,304 shares in the last quarter. Callan Family Office LLC bought a new position in shares of Dynavax Technologies in the 2nd quarter worth $107,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Dynavax Technologies in the 2nd quarter worth $121,000. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Dynavax Technologies during the 2nd quarter worth $127,000. Finally, ELCO Management Co. LLC bought a new stake in Dynavax Technologies during the second quarter valued at about $168,000. 96.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DVAX has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX opened at $11.37 on Monday. The company has a 50 day simple moving average of $10.45 and a two-hundred day simple moving average of $10.35. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -24.72 and a beta of 1.09. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. Dynavax Technologies Corporation has a 12 month low of $9.20 and a 12 month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, analysts predict that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.